Ibotta, Inc.
NYSE:IBTASoftware - Application
-$0.19 today
- Market cap
- $1.14B
- Beta
- -0.58
- P/E (TTM)
- -96.1
- EPS (TTM)
- -$0.30
Volume 0.31M
Average 0.22M
IBTA Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Ibotta, Inc.NYSE: IBTA
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables grows, but more slowly than its trailing trend
Q1 FY2026 accounts receivables of $24.87M rose 73.7% year over year, behind the +1808.4% change in trailing-twelve-month accounts receivables. Sequentially, it rose 507.6% from the prior quarter.
Context
- Accounts receivables amounted to 3.0% of revenue in FY2025, up 1.8 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +73.7% toward the trailing-twelve-month pace of +1808.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 10.24M USD
- Year-over-year change
- +132.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.24M | +132.8% |
| FY2024 | 2024-12-31 | 4.4M | +104.2% |
| FY2023 | 2023-12-31 | (105.71M) | -206.4% |
| FY2022 | 2022-12-31 | (34.51M) | — |
Accounts Receivables vs competitors
How IBTA compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1808.4% is the highest of 9, against a peer median of +155.2%.
- Accounts receivables amounts to 6.1% of revenue for IBTA, versus a peer median of 3.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $70.19M USD | +396.3% | +43.8% | 12.4% | |
| LTM Mar 2026 | $20.79M USD | +1808.4% | — | 6.1% | |
| LTM Mar 2026 | $8.16M USD | +149.3% | — | 3.3% | |
| LTM Mar 2026 | $7.21M USD | -188.8% | -22.3% | 5.6% | |
| LTM Mar 2026 | $3.58M USD | +1122.9% | — | 3.3% | |
| LTM Mar 2026 | $3.53M USD | +161.1% | -3.6% | 1.4% | |
| LTM Mar 2026 | $3.5M USD | -433.4% | -7.4% | 1.0% | |
| LTM Mar 2026 | $3.11M USD | +47.5% | +19.8% | 3.3% | |
| LTM Mar 2026 | $1.45M USD | +216.9% | — | 0.2% | |
| LTM Jun 2026 | CN¥0 CNY | — | — | 0.0% | |
| Peer median (excluding IBTA) | — | +155.2% | -3.6% | 3.3% | |
Competitors are the stored peer set for IBTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (54.86M) | 38.12M | 68.74M | 3.58M |
| Depreciation & Amortization | 6.32M | 6.66M | 8.08M | 8.32M |
| Deferred Income Tax | 0 | 0 | 0 | 3.15M |
| Stock-Based Compensation | 6.5M | 6.99M | 46.92M | 44.14M |
| Change in Working Capital | (26.78M) | (51.6M) | (52.76M) | 24.67M |
| Accounts Receivables | (34.51M) | (105.71M) | 4.4M | 10.24M |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.53M) | 1.82M | (911K) | 355K |
| Other Working Capital | 12.26M | 52.29M | (56.25M) | 14.07M |
| Other Non-Cash Items | 12.32M | 22.55M | 44.94M | 11.42M |
| Operating Cash Flow | (56.5M) | 22.72M | 115.92M | 95.27M |
| Capital Expenditures | (8.26M) | (8.23M) | (10.2M) | (20.29M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (65.98M) | 0 | 0 | 0 |
| Sales of Investments | 38.57M | 27.9M | 0 | 0 |
| Other Investing Activities | (7.48M) | (7.68M) | (9.33M) | (14.01M) |
| Investing Cash Flow | (35.68M) | 19.67M | (10.2M) | (34.3M) |
| Debt Repayment | 73.33M | 0 | 0 | 0 |
| Common Stock Issued | 76.12M | 2.4M | 206.69M | 12.34M |
| Common Stock Repurchased | 0 | 0 | (31.32M) | (232.97M) |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (75.41M) | (12K) | 6.01M | (3.42M) |
| Financing Cash Flow | 74.05M | 2.39M | 181.38M | (224.05M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (18.13M) | 44.77M | 287.1M | (163.08M) |
| Free Cash Flow | (64.76M) | 14.49M | 105.72M | 74.98M |
Ibotta, Inc.
NYSE:IBTA
Intrinsic Alpha fair value
Locked
Current Price
$55.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.